# Empatica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/empatica

- Industry: Medical Devices & Equipment
- Headquarters: Milan, Italy
- Website: www.empatica.com/
- Latest round: Series B (Nov 22, 2022)
- Investors on record: 5

## About

Empatica Inc., based in Milan, Italy, develops innovative medical devices and AI algorithms for remote patient monitoring and clinical research, enhancing healthcare solutions for various neurological conditions. Empatica Inc. was founded in 2011 in Milan, Italy, and specializes in the creation of medical devices and AI technology for health monitoring. The company was co-founded by Matteo Lai, Michele Simonato, Rosalind Picard, and Simone Tognetti. In October 2025, Empatica acquired PKG Health, a leader in movement disorder algorithms, to expand its capabilities in Parkinson’s disease monitoring. Empatica specializes in advanced medical devices and AI-driven algorithms designed for remote patient monitoring and clinical research. Its flagship offerings include the Empatica Health Monitoring Platform, which integrates the EmbracePlus wearable device and a comprehensive care software suite. The platform is engineered to collect and analyze raw health data and digital biomarkers, facilitating real-time monitoring across various therapeutic areas, including epilepsy and other neurological conditions. With a focus on ease of use, these solutions cater to both clinical environments and everyday life, enabling pharmaceutical companies, contract research organizations, and healthcare providers to enhance patient care and research outcomes. Empatica's products are available in over 160 countries, with extensive localization to support more than 40 languages, thereby ensuring accessibility to a wide array of end users, from patients to trial participants and academic researchers. Following the October 2025 acquisition of PKG Health, Empatica has significantly expanded its revenue potential by integrating PKG’s validated movement disorder algorithms into its platform. This move enables Empatica to offer exclusive digital endpoints for Parkinson’s disease monitoring, which are now available to over 150 hospitals and clinical sites across Europe, Australia, and the U.S. Following the acquisition, Empatica’s robust, FDA-cleared wearable technology and health monitoring platform with PKG Health’s validated algorithms for movement disorder monitoring, significantly broadening Empatica’s reach and market potential within neurology research, clinical care, and diagnostics. Empatica is focused on expanding its product portfolio and global footprint. The launch of EmbraceMini in 2025 and the CE MDR certification for EpiMonitor in Europe mark key milestones in its growth strategy.

## Funding rounds

- Series B, Nov 22, 2022 — Sanofi Ventures, RA Capital Management, Black Opal Ventures
- Series A, Dec 29, 2016 — CDP Venture Capital, Innogest

## Investors

- CDP Venture Capital (https://capitalatlas.ai/funds/cdp-venture-capital) — Series A
- Innogest (https://capitalatlas.ai/funds/innogest) — Series A
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Black Opal Ventures (https://capitalatlas.ai/funds/black-opal-ventures) — Series B